02186 LUYE PHARMA
- 2.950
- +0.100+3.51%
LUYE PHARMA News
China Grants Marketing Approval to Luye Pharma's Anti-Schizophrenia Tablets
China's medical products administrator granted marketing approval to Luye Pharma Group's (HKG:2186) Meibirui antipsychotic drug for schizophrenia, according to a Tuesday filing with the Hong Kong Stoc
Luye Pharma (02186): Mebipuri (Paliperidone Palmitate Injection) has been approved for listing in China.
Luye Pharma (02186) announced that its independently-developed second-generation long-acting antipsychotic injection, Mebiray (Paliperidone Palmitate Injection), has been approved by the National Medical Products Administration of the People's Republic of China for the treatment of acute and maintenance phases of schizophrenia.
Express News | Luye Pharma - Meibirui (Paliperidone Palmitate Injection) Approved for Marketing in China by Nmpa
Sinopec SSC (01033) signed a turnkey fixed-price contract with Saudi Aramco for the MGS Phase III Pipeline Project Groups 6 and 7 domestic procurement and construction, with a total investment of approximately RMB 7.956 billion.
Luye Pharma (02186) submitted a new drug application for Lisinopril Transdermal Patch (2 times/W) in Japan; Kingkey Fin Int (01468) signed a memorandum of understanding with PRIME on potential cooperation in developing and promoting solar power plants, energy and environmental technology solutions.
Express News | Luye Pharma - Towa Pharmaceutical Filed Nda in Japan for Rivastigmine Twice Weekly Transdermal Patch
Private Companies Who Have a Significant Stake Must Be Disappointed Along With Institutions After Luye Pharma Group Ltd.'s (HKG:2186) Market Cap Dropped by HK$940m
Key Insights Significant control over Luye Pharma Group by private companies implies that the general public has more power to influence management and governance-related decisions 56% of the busine
Changes in Hong Kong stocks | The collective decline in pharmaceutical stocks will improve the quality and expansion of pharmaceutical procurement, which is expected to form a national alliance for procurement
Pharmaceutical stocks fell collectively today. As of press release, Luye Pharmaceuticals (02186) fell 7.72% to HK$2.75; Kaituo Pharmaceutical-B (09939) fell 7.35% to HK$1.26; Zhongsheng Pharmaceuticals (01177) fell 5.75% to HK$2.95; and Cinda Biotech (01801) fell 4.61% to HK$38.3.
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Luye Pharmaceuticals (02186.HK) gains 3.569,500 shares from UBS Group AG
Glonghui, May 9 | According to the latest equity disclosure data on the Stock Exchange, on May 2, 2024, Luye Pharmaceutical (02186.HK) received UBS Group AG's good holdings of 3.569,500 shares at an average price of HK$2.9389 per share on the market, involving approximately HK$10.49 million. After the increase in holdings, UBS Group AG's latest number of good positions was 452,878,777 shares, and the holding ratio increased from 11.94% to 12.04%.
綠葉製藥：年報 2023
Luye Pharma Group Ltd. (HKG:2186) Not Lagging Market On Growth Or Pricing
With a price-to-earnings (or "P/E") ratio of 17.8x Luye Pharma Group Ltd. (HKG:2186) may be sending very bearish signals at the moment, given that almost half of all companies in Hong Kong have P/E ra
[Broker Focus] Tianfeng Securities maintains Luye Pharmaceutical's (02186) “buy” rating, indicating that the main types of core business have large market space
Jinwu Financial News | According to Tianfeng Securities Research Report, Luye Pharmaceutical (02186) announced 2023 results: overall operating revenue of 6.14 billion yuan in 2023, up 2.7% year on year, product sales revenue of 5.63 billion yuan, up 11.2% year on year, and net profit to mother of 533 million yuan, down 11.9% year on year. The decline in net profit is mainly due to a decrease in the share of authorized revenue. The company's overall performance was in line with expectations. The bank mentioned that subsequent sales volume of core products and progress in the research pipeline are worth looking forward to, and there is plenty of room for reasonable valuation. According to this bank, considering the outstanding advantages of the company's new products, there will be many
Huaan Securities: Maintaining Luye Pharmaceutical's (02186) “Buy” Rating Rapid Growth in Sales Revenue in 2023
Huaan Securities is optimistic about the rapid release of new oncology products such as Luye Pharmaceuticals (02186) and Baituwei after they are launched.
Changes in Hong Kong stocks | Luye Pharmaceutical (02186) fell nearly 5% in the afternoon, annual net profit fell 11.9% year-on-year, and sales revenue of oncology products fell 8%
Luye Pharmaceutical (02186) fell nearly 5% in the afternoon. As of press release, it was down 4.58% to HK$2.71, with a turnover of HK$28.295,800.
Luye Pharmaceutical Announces 2023 Annual Results Profit attributable to shareholders of 533 million yuan, a year-on-year decrease of 11.94%
Luye Pharmaceutical (02186) announced its annual results for the year ended December 31, 2023. The group achieved revenue of 6.143 billion yuan (RMB, same below) during the period, an increase of 2.7% over the previous year; profit attributable to shareholders was 533 million yuan, a decrease of 11.94% year on year; and basic profit per share was 14.29 points.
Is There An Opportunity With Luye Pharma Group Ltd.'s (HKG:2186) 27% Undervaluation?
Key Insights The projected fair value for Luye Pharma Group is HK$3.88 based on 2 Stage Free Cash Flow to Equity Luye Pharma Group is estimated to be 27% undervalued based on current share price of
Luye Pharmaceutical Announces 2023 Annual Results
Product sales have grown steadily, and the financial structure has been significantly optimized, Shanghai, March 27, 2024/PRNewswire/ -- On March 27, Luye Pharmaceutical Group (2186.HK) announced its 2023 annual results and business progress to date. During the reporting period, the Group's revenue was about 6.14 billion yuan, up 2.7% year on year; EBITDA was about 2.08 billion yuan, up 14.6% year on year; profit before tax was about 70 billion yuan, up 4.5% year on year. The Group's balance ratio was approximately 46.9%, down 7.6 percentage points from the previous year. Of operating income, production
LUYE PHARMA: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Global Transdermal Medical Patch Market Analysis 2024-2029, Featuring Novartis, Viatris, Nitto Denko, Luye Pharma, Hisamitsu Pharmaceutical, Medline Industries, Corium, UCB, Teikoku Pharma and More
DUBLIN, March 25, 2024 /PRNewswire/ -- The "Global Transdermal Medical Patch Market: Analysis By Type, By Application, By Distribution Channel, By Region Size & Forecast to 2029" report has been adde
Luye Pharmaceutical (02186.HK) held a board meeting on March 27 to approve annual results
Glonghui, March 14, 丨 Luye Pharmaceutical (02186.HK) announced that the company will hold a board meeting on March 27, 2024 (Wednesday) to approve (among other things) the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and consider paying a final dividend (if any).
Analysis
Price Target
No Data
